The pharmaceutical company got an approval from Central Licensing Approving Authority, Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare for manufacture, sale and distribution of Isavuconazonium Sulfate API and finished formulation Isavuconazole for injection 200 mg/vial.

Isavuconazole is a systemic antifungal drug of triazole class. The drug is used for the treatment of Invasive Aspergillosis and Invasive Mucormycosis in patients of 18 years of age and older. Isavuconazole has already been approved by US-FDA on 6 March 2015 and European Medicines Agency (EMA) on 15 October 2015.

Gufic is engaged in the research and development, manufacturing, marketing, distribution and sale of pharmaceutical and allied products. The pharmaceutical company's net profit advanced 36% to Rs 21.03 crore on 3.3% increase in net sales to Rs 172.07 crore in Q3 FY22 over Q3 FY21.

Shares of Gufic bioscience slipped 1.82% to end at Rs 247.85 on BSE.